A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 1RecruitingNCT07558915

Genentech, Inc.160 enrolled

Overview

This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors \[PIs\], immunomodulators \[IMiDs\], and anti-cluster of differentiation 38 \[anti-CD38\] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

160

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

RO7851624DRUG

Participants will receive RO7851624 as per the schedule described in the protocol.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Life expectancy of at least 12 weeks. * Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria. * Measurable disease. Exclusion Criteria: * Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) with insufficient washout prior to ﬁrst dose of study treatment. * Autologous stem cell transplant (SCT) with insufficient time prior to ﬁrst dose of study treatment. * Prior allogeneic SCT. * Prior solid organ transplantation.

Locations (1)

Peter MacCallum Cancer Center

Parkville, Victoria, Australia

RECRUITING